Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 12/20 | 0.66 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22249597 | 0.84 | NLRP3 (0.68) | NLRP3APPJAK2 | |
| SCHEMBL22249415 | 0.83 | NLRP3 (0.73) | NLRP3APPJAK2 | |
| SCHEMBL22249414 | 0.83 | NLRP3 (0.67) | NLRP3PDPK1APPJAK2 | |
| SCHEMBL22249413 | 0.83 | NLRP3 (0.67) | NLRP3PDPK1APPJAK2 | |
| SCHEMBL22249257 | 0.82 | NLRP3 (0.66) | NLRP3PDPK1APPJAK2NOS3 | |
| SCHEMBL22249392 | 0.82 | NLRP3 (0.68) | NLRP3APPJAK2 | |
| SCHEMBL22249592 | 0.81 | NLRP3 (0.67) | NLRP3 | |
| SCHEMBL22249320 | 0.81 | NLRP3 (0.67) | NLRP3PDPK1APPJAK2NOS3 | |
| SCHEMBL22249394 | 0.81 | NLRP3 (0.67) | NLRP3DYRK1AAPPJAK2RIPK2 | |
| SCHEMBL22249450 | 0.81 | NLRP3 (0.67) | NLRP3APPJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |